🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At the upcoming AACR Annual Meeting in Chicago, we’ll be presenting preclinical data on SOT106 and SOT109, our two most advanced #ADC programs to treat solid tumors. Full presentation details are in our press release: sotio.com/news-publicati… #AACR25 #Biotechnology

Irena Adkins, our Director of Pharmacology, will present at the Hanson Wade Tumor Models Summit Nordics in Stockholm, Sweden. She’ll discuss how preclinical models shape #oncology research, their role in advancing therapies, and the key challenges in translating findings to the

Jitka Fučíková will be presenting a poster sharing insights on the role of tertiary lymphoid structures (TLS) and B cells in the #tumor microenvironment at the upcoming VIB Training & Conferences “Immune Niches in Cancer & Inflammation” conference. #Immunotherapy #CancerResearch #Oncology

Our paper on SOT201 — a novel immunocytokine combining IL-15 with PD-1 inhibition — has just been published in Journal for ImmunoTherapy of Cancer. We report that in preclinical studies SOT201 exhibits strong anti-tumor efficacy, with several complete responses in all tested mouse tumor models. It also

At the AACR Annual Meeting this week we shared new data from our two most advanced #ADC candidates, underscoring their best-in-class potential as solid tumor treatments. In preclinical studies, SOT109 (CDH17 ADC) exhibited potent efficacy and a favorable safety profile in

As the AACR Annual Meeting comes to a close, we appreciate the opportunity to share the latest data from two promising antibody-drug conjugate (#ADC) programs for solid tumors — SOT106 and SOT109. The interest in the presentations by our colleagues Michaela Fojtů and Nataliia

Next week we’re heading to the 25th #BioEquityEurope meeting — Europe’s premier stage for rising biotechs to connect with global investors and biopharma leaders. We’re looking forward to connecting with fellow #oncology experts, and sharing how our innovative pipeline,

Next stop: Barcelona for the EACR Immuno-Oncology Breakthroughs conference, where SOTIO scientists will deliver two presentations. Jana Tománková will present advanced strategies for integrative molecular and spatial analysis of intratumoral tertiary lymphoid structures for

In a recent Q&A with Drug Discovery World, our Chief Scientific Officer Martin Steegmaier, discusses how SOTIO is addressing some of the most critical challenges in #ADC discovery and development. He reviews the design of bispecific ADCs, the importance of target selection, and the need

On #ClinicalTrialsDay, we’re proud to recognize the dedicated professionals on Team SOTIO who are driving innovation in #cancer treatment through clinical research. Hear from our colleagues on what their work in clinical research means to them and what drives their commitment to

In a newly released Q&A with Discover Pharma, Martin Steegmaier, Chief Scientific Officer at SOTIO, discusses SOT109, our investigational antibody-drug conjugate targeting CDH17. Read the full article here: discover-pharma.com/sotios-sot109-…

We’re looking forward to attending this year’s ASCO conference in Chicago. We’re proud to be part of this global gathering of researchers, clinicians, and innovators working to shape the future of #cancer treatment. If you’ll be on the ground at ASCO, please reach out to connect

We’re developing the next generation of potent immunotherapies for patients with solid tumors. In honor of #CancerImmunotherapy Month, we are spotlighting one of the unique approaches we’re taking to activating the immune system to fight #cancer: immunocytokines. Our

We’re proud to share that for the 8th time, SOTIO and SCTbio colleagues participated in ‘Bike to Work’ month and chose a healthier, more sustainable way to commute. This year, 26 participants cycled an impressive 8,831 km, helping to prevent roughly 1,413 kg of CO2 emissions and

We will attend the Biotechnology Innovation Organization convention in Boston next week! Interested in meeting? Reach out to us. #BIO2025 #Biotechnology #CancerResearch #DrugDevelopment

At SOTIO, we are advancing multiple technology platforms to develop potent therapies for patients with solid tumors. Next week at the @EACRNews Congress, we will present four posters that share insights into tumor immunology and its relevance for #cancer immunotherapy. Together

Last week employees from our U.S. and European offices reunited for our yearly SOTIO and SCTbio Day, an event dedicated to connection, creativity, and collaboration. Events like these remind us that innovation is built not only in the lab, but in the culture we create as a team.

Sarcoma treatment remains a critical unmet need in #oncology, with limited treatment options for patients. We’re advancing SOT106, a next-gen #ADC that delivers potent payloads directly to tumors while saving healthy tissue. SOT106’s promising preclinical data was featured in an

The global antibody-drug conjugate (#ADC) market is rapidly expanding due to increasing cancer cases, technological breakthroughs, and a heightened demand for targeted therapies. SOT106 and SOT109, our two potentially best-in-class ADCs, have demonstrated robust anti-tumor